49.15
0.47%
-0.21
Sanofi ADR stock is currently priced at $49.15, with a 24-hour trading volume of 2.95M.
It has seen a -0.47% decreased in the last 24 hours and a -1.25% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $49.28 pivot point. If it approaches the $48.73 support level, significant changes may occur.
Previous Close:
$49.36
Open:
$48.84
24h Volume:
2.95M
Market Cap:
$120.95B
Revenue:
$50.28B
Net Income/Loss:
$5.86B
P/E Ratio:
15.49
EPS:
3.1735
Net Cash Flow:
$19.45B
1W Performance:
+6.11%
1M Performance:
-1.25%
6M Performance:
-7.88%
1Y Performance:
-12.61%
Sanofi ADR Stock (SNY) Company Profile
Name
Sanofi ADR
Sector
Industry
Phone
33 1 53 77 40 00
Address
54, Rue La Boétie, Paris
Sanofi ADR Stock (SNY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
Jan-16-24 | Resumed | UBS | Buy |
Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
Oct-30-23 | Downgrade | Stifel | Buy → Hold |
Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
Dec-13-22 | Resumed | Morgan Stanley | Overweight |
Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
Aug-09-22 | Downgrade | UBS | Buy → Neutral |
May-23-22 | Initiated | SVB Leerink | Outperform |
Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Jan-15-21 | Initiated | Deutsche Bank | Sell |
Sep-29-20 | Initiated | Berenberg | Hold |
Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-03-19 | Initiated | Bernstein | Outperform |
Aug-14-19 | Upgrade | UBS | Neutral → Buy |
Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
Oct-09-18 | Initiated | Guggenheim | Neutral |
Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
Mar-23-18 | Upgrade | Liberum | Hold → Buy |
Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi ADR Stock (SNY) Latest News
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks Investment Research
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Zacks Investment Research
Sanofi (SNY) Q1 2024 Earnings Call Transcript
The Motley Fool
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Zacks Investment Research
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Benzinga
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Zacks Investment Research
Sanofi ADR Stock (SNY) Financials Data
Sanofi ADR (SNY) Revenue 2024
SNY reported a revenue (TTM) of $50.28 billion for the quarter ending December 31, 2023, a +5.47% rise year-over-year.
Sanofi ADR (SNY) Net Income 2024
SNY net income (TTM) was $5.86 billion for the quarter ending December 31, 2023, a -33.26% decrease year-over-year.
Sanofi ADR (SNY) Cash Flow 2024
SNY recorded a free cash flow (TTM) of $19.45 billion for the quarter ending June 30, 2022.
Sanofi ADR (SNY) Earnings per Share 2024
SNY earnings per share (TTM) was $2.3435 for the quarter ending December 31, 2023, a -17.28% decline year-over-year.
About Sanofi ADR
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Cap:
|
Volume (24h):